Alta Partners

Type

Venture Capital

Status

Active

Location

Jackson, United States

Total investments

271

Average round size

36M

Portfolio companies

137

Rounds per year

9.68

Lead investments

47

Follow on index

0.49

Exits

78

Stages of investment
Private EquityEarly Stage VentureLate Stage Venture
Areas of investment
BiotechnologyHealth CareHealth DiagnosticsGeneticsManufacturingMedical DeviceMedicalPharmaceuticalTherapeuticsBiopharma

Summary

Alta Partners appeared to be the VC, which was created in 1996. The leading representative office of defined VC is situated in the San Francisco. The venture was found in North America in United States.

The increased amount of exits for fund were in 2014. Considering the real fund results, this VC is 1 percentage points more often commits exit comparing to other organizations. When the investment is from Alta Partners the average startup value is 10-50 millions dollars. This Alta Partners works on 1 percentage points more the average amount of lead investments comparing to the other organizations. The common things for fund are deals in the range of 10 - 50 millions dollars. The high activity for fund was in 2007. Despite it in 2019 the fund had an activity. The fund is generally included in 7-12 deals every year.

The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Alta Partners, startups are often financed by Venrock, SV Health Investors, Atlas Venture. The meaningful sponsors for the fund in investment in the same round are RiverVest, OrbiMed, Bay City Capital. In the next rounds fund is usually obtained by New Enterprise Associates, Venrock, HBM Healthcare Investments AG.

Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Kite Pharma, Intarcia Therapeutics, ZS Pharma The fund has exact preference in some founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. Among the most popular fund investment industries, there are Pharmaceutical, Biotechnology. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.

The current fund was established by Garrett Gruener, Guy P. Nohra, Jean Deleage. We also calculated 8 valuable employees in our database.

Show more

Investor highlights

Industry focus
Healthcare

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Last fund

Fund size
USD 275000000
Fund raised date
2021-02-18

Analytics

Total investments
271
Lead investments
47
Exits
78
Rounds per year
9.68
Follow on index
0.49
Investments by industry
  • Biotechnology (176)
  • Health Care (147)
  • Medical (83)
  • Therapeutics (62)
  • Pharmaceutical (52)
  • Show 75 more
Investments by region
  • United States (238)
  • Grenada (1)
  • France (3)
  • Canada (1)
  • Denmark (5)
  • Show 10 more
Peak activity year
2007
Number of Unicorns
5
Number of Decacorns
5
Number of Minotaurs
5

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
18
Avg. valuation at time of investment
120M
Group Appearance index
0.98
Avg. company exit year
11
Avg. multiplicator
1.07
Strategy success index
0.80

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Novome Biotechnologies 13 Sep 2022 Biotechnology, Therapeutics, Biopharma Early Stage Venture 43M United States, California, South San Francisco
Progentos Therapeutics 20 May 2024 Early Stage Venture 65M United States, Massachusetts, Watertown

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.